This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Behavioural disorders
  • /
  • DRD4 Exon 3 Genotype and ADHD: Randomized Pharmaco...
Journal

DRD4 Exon 3 Genotype and ADHD: Randomized Pharmacodynamic Investigation of Treatment Response to Methylphenidate.

Read time: 1 mins
Published:28th Nov 2017
Author: Naumova D, Grizenko N, Sengupta SM, Joober R.
Availability: Pay for access, or by subscription
Ref.:World J Biol Psychiatry. 2017:1-28.
DOI:10.1080/15622975.2017.1410221

Objectives: Dopamine plays an important role in modulating attention and motor behaviors, dimensions altered in attention deficit/hyperactivity disorder (ADHD). Numerous association studies have linked dopamine receptor 4 (DRD4) to increased risk of ADHD. This study investigated the effect of DRD4 exon 3 polymorphism on child behaviours in response to treatment with methylphenidate (MPH).

Methods: 374 children diagnosed with ADHD (ages 6-12) were evaluated under three experimental conditions: baseline, placebo and MPH (0.5 mg/kg/day). This was a 2-week prospective within-subject, placebo-controlled, crossover trial. The Conners' Global Index for parents and for teachers was used to evaluate the behaviours of the children. One-way repeated measures analysis of variance was used to test the effect of the interaction between DRD4 genotype and experimental conditions.

Results: A significant interaction between DRD4 genotype and treatment was detected when the child's behaviour was evaluated by the parents (p = 0.035, effect size of 0.014), driven by a better treatment response in children homozygous for long 7-repeat allele.

Conclusions: According to the parent assessment, children homozygous for the long 7-repeat allele were more responsive to experimental condition. This is the largest pharmacogenetic investigation of the effect of DRD4 exon 3 polymorphism in childhood ADHD.

Read abstract on library site

Access full article